Exelixis, Inc. (EXEL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States.
Is Exelixis, Inc. stock overvalued or undervalued in 2026?
Exelixis, Inc. (EXEL) trades at 20.8× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Exelixis, Inc.
Market cap $17B · 52 weeks $38 – $66 (0 % below the high) · P/E 20.8× · 2027 expected P/E 18.6× · Dividend none · Next earnings October 29, 2026 · expected EPS $0.89 · Closing price, Oct 28 · accounts published Aug 5.
- Valuation: P/Sales 7.9× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 4.6 %, fails.
- Market cap / Cash 17.0×, fails.
- Annual cash burn $3.26, passes.
- Total Debt 0.2×, passes.
Against its peers (reference peers) — Exelixis, Inc.: P/E 20.8×; EV/EBITDA 15.8×; ROIC 37.9 %; $16.7B. Incyte Corporation (P/E 14.9×; EV/EBITDA 9.6×; ROIC 24.6 %; $23.7B), Genmab A/S (P/E 45.1×; EV/EBITDA 22.4×; ROIC 9.9 %; $35.2B), HUTCHMED (China) Limited (P/E 140×; EV/EBITDA —; ROIC -2.1 %; $2.5B).
Profitability
| Return on Equity | 42.49% |
| Return on Invested Capital | 37.87% |
| Return on Assets | 34.50% |
| Gross Margin | 96.48% |
| Operating Margin | 39.88% |
| Net Margin | 35.33% |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 3.46 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 12.62 |
Price Performance
| 1 month | +13.01% |
| 3 months | +24.99% |
| Year-to-date | +51.22% |
| 1 year | +68.10% |
| 3 years | +227.47% |
| 5 years | +208.14% |
| 10 years | +525.87% |
Related companies: INCY · RVMD · GMAB · HCM · AZN
Explore sector: Healthcare · Biotechnology
More sections of EXEL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks